P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY

作者
Nirav Niranjan Shah,Richard Thomas Maziarz,Caron Alyce Jacobson,Iris Isufi,Monalisa Ghosh,Matthew L. Ulrickson,Miguel‐Angel Perales,Matthew Alexander Lunning,Nancy M. Hardy,Anna Wijatyk,Marek Ancukiewicz,Mrs. Madhavi Nallewar,Kimberly C. Coleman,Bethany Cheree Prudner,Esther Eromosele,Remigiusz Kaleta,David Bernard Miklos
出处
期刊:HemaSphere [Wolters Kluwer]
卷期号:7 (S3): e07109dc-e07109dc 被引量:6
标识
DOI:10.1097/01.hs9.0000971432.07109.dc
摘要

Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: DALY II USA is the first multicenter trial of fresh, bispecific targeted CD20/CD19, chimeric antigen receptor (CAR) T-cell therapy for patients (pts) with R/R diffuse large B-cell lymphoma (DLBCL). While CD19 CAR T-cell therapy is an established treatment for pts with R/R DLBCL, relapse remains a clinical challenge. One proposed mechanism of resistance is either loss of epitope, recognition or downregulation of the CD19 receptor. To improve outcomes, dual targeting of B-cell receptor has been proposed. Reported here is the preplanned interim futility analysis after treatment of 22 evaluable pts. Aims: To assess safety and efficacy of dual CAR-T therapy with zamtocabtagene autoleucel (zamto-cel) administered fresh in R/R DLBCL Methods: Eligible pts were >18 y, ECOG PS 0-1, with R/R DLBCL after ≥2 prior lines of systemic therapy. No bridging chemotherapy was allowed. Apheresis material was shipped fresh without cryopreservation to a central manufacturing site. A fixed 12-day process of CAR-T production was performed using the CliniMACS Prodigy® (Miltenyi Biotec). A single infusion of 2.5x106 cells/kg fresh zamto-cel was administered after lymphodepletion which was initiated during manufacturing to facilitate a fresh infusion. Evaluation of response rate is the primary objective of this study. Results: As of 1 Sep 2022, 28 pts have enrolled (All treated) with 22 evaluable per protocol. Most (69%) of treated patients presented advanced disease with IPI score of at least 3 and abnormal baseline LDH and 28% were previously treated with CD19 and or CD79 targeting agents. Six pts were not included in the primary efficacy analysis. One received a frozen product and 5 received a non-conforming fresh product. Per Independent Radiology Committee (IRC) 18 (82%) of 22 evaluable pts had either complete (CR - 46%) or partial response (PR – 36%) exceeding preplanned futility threshold. Response rate in evaluable set was similar to that in all-treated population (Tbl. 1). Post progression biopsy were available in 5 pts. There was no isolated CD19 loss, but 1pt had dual target loss CD19+CD20 in relation to the pre-treatment status. PFS at 6 months for evaluable pts were 64% and 61% for all treated. The treatment was well tolerated. Among all 28 treated pts., there were no grade 3-4 CRS events and only two transient and reversible Grade 3 ICANS (9%). There were no treatment related mortality. Summary/Conclusion: Prespecified efficacy threshold of zamto-cel was exceeded in the interim analysis Treatment demonstrated a favorable safety profile, with promising ORR and PFS in advanced DLBCL population often pre-treated with agents not available in the previous similar studies. We also demonstrate the feasibility of a rapid manufacturing process with 100% fresh infusion in eligible pts. Table 1: Objective Response Rate per IRC and per Site - Evaluable Set (n=22) All Treated (n=28) IRC Per Site IRC Per Site ORR 18 (82%) 17 (77%) 22 (79%) 20 (71%) CR 10 (46%) 11 (50%) 14 (50%) 13 (46%) PR 8 (36%) 6 (27%) 8 (29%) 7 (25%) SD 1 (4%) 2 (9%) 1 (4%) 2 (7%) PD 3 (14%) 3 (14%) 5 (17%) 5 (18%) IRC – Independent Radiology Committee Keywords: Diffuse large B cell lymphoma, CD19, CAR-T, CD20

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
杨媛发布了新的文献求助10
刚刚
hmm萌萌哒哒完成签到,获得积分10
刚刚
小吴完成签到 ,获得积分10
1秒前
Totoya完成签到,获得积分10
1秒前
大方雪卉完成签到,获得积分10
1秒前
如果Ta完成签到,获得积分10
1秒前
爱哥哥的妹妹关注了科研通微信公众号
1秒前
一区的神完成签到,获得积分10
1秒前
imEda完成签到,获得积分10
1秒前
灶鲜森发布了新的文献求助10
2秒前
夏冰雹完成签到 ,获得积分10
2秒前
2秒前
ff完成签到,获得积分10
2秒前
木林森幻完成签到,获得积分10
2秒前
瑞一杯小黄油拿铁完成签到,获得积分10
2秒前
章鱼哥发布了新的文献求助30
3秒前
科研通AI65的应助被canhui采纳,获得10
3秒前
DOC_XIONG的应助被canhui采纳,获得10
3秒前
zhyclover完成签到,获得积分10
3秒前
cai完成签到 ,获得积分10
4秒前
4秒前
4秒前
王欣瑶完成签到 ,获得积分10
5秒前
小朵完成签到 ,获得积分10
5秒前
DuDu完成签到,获得积分10
5秒前
Cr的应助被研友来科研啊采纳,获得10
6秒前
xiakui完成签到,获得积分10
7秒前
Youdge完成签到,获得积分0
7秒前
yu完成签到,获得积分10
8秒前
baozeNG发布了新的文献求助10
8秒前
chiyu完成签到,获得积分10
8秒前
csu_zs完成签到,获得积分10
9秒前
传奇3的应助被王电催化采纳,获得10
9秒前
9秒前
fairytaler的应助被他说采纳,获得10
10秒前
彭于晏的应助被躺赢的猴哥采纳,获得10
10秒前
lucky完成签到 ,获得积分10
10秒前
传统的松鼠完成签到 ,获得积分10
10秒前
愉快的夏菡完成签到,获得积分10
11秒前
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180407
求助须知:如何正确求助?哪些是违规求助? 9570403
关于积分的说明 21811831
捐赠科研通 7776452
什么是DOI,文献DOI怎么找? 3433277
关于科研通互助平台的介绍 2557499
邀请新用户注册赠送积分活动 2479105